Semaglutide (5 mg vial)

Semaglutide (5 mg vial)

Primary use: Weight loss & glycemic control (obesity, metabolic disease)

Mechanism / class: GLP-1 receptor agonist (incretin mimetic)

Key effects:

• Suppresses appetite via hypothalamic satiety signaling
• Slows gastric emptying → earlier and prolonged fullness
• Enhances glucose-dependent insulin secretion
• Reduces post-prandial glucose spikes

Clinical distinction:
Acts centrally and peripherally to reduce caloric intake through physiologic satiety—not a stimulant, not a fat burner, and not a metabolism booster.

Semaglutide is supplied strictly for research and development purposes only. Not for human or veterinary consumption.